Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Utikal
Selma Ugurel

Showing results (261-270 of 490) with videos related to

Pageof 49
Sort By:
Frontiers in Immunology|April 1, 2021
Harnessing Mesenchymal Stromal Cells for the Engineering of Human Hematopoietic NichesAlice Pievani, Roberto Savoldelli, Juliane Poelchen, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREGSophia Kreft, Valerie Glutsch, Anne Zaremba, et al.
Journal for Immunotherapy of Cancer|May 7, 2020
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOGSarah Knispel, Andreas Stang, Lisa Zimmer, et al.
Cancer Immunology, Immunotherapy : CII|October 3, 2007
Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapySelma Ugurel, David Schrama, Gunhild Keller, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2019
MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case seriesSelma Ugurel, Ivelina Spassova, Jonas Wohlfarth, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanomaSelma Ugurel, Felix Kiecker, Stefan Fröhling, et al.
European Journal of Cancer (Oxford, England : 1990)|May 30, 2018
MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patientsMichael Constantin Kirchberger, Selma Ugurel, Johanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2016
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipientSaskia Herz, Thomas Höfer, Matina Papapanagiotou, et al.
BMC Medical Genomics|March 2, 2016
SOX5 is involved in balanced MITF regulation in human melanoma cellsTheresa Kordaß, Claudia E M Weber, Marcus Oswald, et al.
Pageof 49

Showing results (261-270 of 490) with videos related to

Sort By:
Pageof 49
Frontiers in Immunology|April 1, 2021
Harnessing Mesenchymal Stromal Cells for the Engineering of Human Hematopoietic NichesAlice Pievani, Roberto Savoldelli, Juliane Poelchen, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREGSophia Kreft, Valerie Glutsch, Anne Zaremba, et al.
Journal for Immunotherapy of Cancer|May 7, 2020
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOGSarah Knispel, Andreas Stang, Lisa Zimmer, et al.
Cancer Immunology, Immunotherapy : CII|October 3, 2007
Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapySelma Ugurel, David Schrama, Gunhild Keller, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2019
MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case seriesSelma Ugurel, Ivelina Spassova, Jonas Wohlfarth, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanomaSelma Ugurel, Felix Kiecker, Stefan Fröhling, et al.
European Journal of Cancer (Oxford, England : 1990)|May 30, 2018
MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patientsMichael Constantin Kirchberger, Selma Ugurel, Johanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2016
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipientSaskia Herz, Thomas Höfer, Matina Papapanagiotou, et al.
BMC Medical Genomics|March 2, 2016
SOX5 is involved in balanced MITF regulation in human melanoma cellsTheresa Kordaß, Claudia E M Weber, Marcus Oswald, et al.
Pageof 49